Key facts
- Notable investors include European Commission, Agroinncuba, Biozell Ventures, CEEI, Capsa Vida — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Darwin Bioprospecting Excellence
- ·The full record, as it builds
Funding rounds
No funding rounds for Darwin Bioprospecting Excellence are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Darwin Bioprospecting Excellence
Developer of a bioprospecting platform designed to provide microbial research for the medical field. The company's platform deals with microbiome sequencing, food starters, probiotics, energy and environment research in carotenoid-producing microorganisms, adaptation, and optimization of bioinformatics pipelines for the MinION technology, enabling medical research institutes to do personalized sampling, culturing, sequencing, and production strategies.
- Sector
- Healthcare
- HQ
- Paterna, Spain
- Founded
- 2016
- Employees
- 23
- Website
- darwinbioprospecting.com/
- Ownership
- Privately Held (backing)
Darwin Bioprospecting Excellence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Darwin Bioprospecting Excellence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Darwin Bioprospecting Excellence in its N-PORT filings yet. We sweep new filings monthly.